BioVie Unveils Phase 2 Trial Design for Long COVID Neurological Symptoms Treatment
BioVie Inc. is leveraging its experience in neuroinflammation to target the Long COVID market with bezisterim, an oral anti-inflammatory...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
BioVie Inc. is leveraging its experience in neuroinflammation to target the Long COVID market with bezisterim, an oral anti-inflammatory...
Creative Medical Technology Holdings (CELZ) has received FDA Fast Track designation for CELZ-201-DDT, its allogeneic perinatal cell therapy for...
Tiziana Life SciencesLife Sciences has received FDA clearance for a Phase 2a trial of intranasal foralumab in patients with...
IO Biotech’s Phase 3 trial of Cylembio plus pembrolizumab in advanced melanoma narrowly missed statistical significance on its primary...
FoRx Therapeutics has dosed the first patient in a Phase 1 trial of FORX-428, an oral PARG inhibitor, in...
The FDA accepted Arvinas and Pfizer’s New Drug Application (NDA) for vepdegestrant, an oral PROTAC estrogen receptor degrader, for...
Dogwood Therapeutics announced enrollment of the first 50 patients in its Phase 2b trial of Halneuron for chemotherapy-induced neuropathic...
Inadequate disease control remains a persistent challenge in the management of idiopathic inflammatory myopathies (IIM), particularly for dermatomyositis (DM)...
A propensity-matched analysis of 410 liver transplant patients from the GUARDIAN-Liver Registry showed a 51% reduction in early allograft...
PharmAla Biotech has delivered over 500 capsules of its LaNeo 40mg MDMA to the Merhavim Mental Health Centre in...